

# Pressure BioSciences, Inc.

10:10 11 Jun 2020

## Pressure BioSciences merger partner receives \$3.5 million order for hand sanitizer product

Pressure BioSciences Inc (OTCQB:PBIO) said its merger partner, SkinScience Labs, has received an initial \$3.5 million order for its newly developed dermatological hand sanitizer product.

Pressure BioSciences agreed to acquire SkinScience in April and the merger is expected to close on by June 30.

### READ: Pressure BioSciences eyeing around \$2.4 million in 1Q 2021 as it sells its first manufacturing run of BaroShear K45 systems

SkinScience is the parent company of the Dr Denese skin care and anti-aging product lines, developed by Adrienne Denese, an industry leader in scientific skin care breakthrough technologies.

"Our goal has always been to develop and supply the highest quality of personal care products expected by our very loyal customer base. Over the past few months, shortages of hand sanitizers have been reported by stores all over the US. With SkinScience Labs' nearly two decades of experience in formulation, manufacturing, and distribution, and my expertise and training as a scientist and physician, it became clear that we could become an important new part of the solution. With particular focus on the adverse effects that the high alcohol content in typical hand sanitizers have on skin, we went back to the lab and formulated a premium quality, dermatologically driven hand sanitizer. We recently made the decision to release this very effective, premium product to the market," Denese said in a statement.

Following the merger, Pressure BioSciences will change its name to Availa Bio and will be led by Jim Morrison, the former president of L'Oreal.


"Dr Adrienne Denese is an accomplished doctor, scientist, businesswoman, and skin care visionary. It therefore came as no surprise that she chose to expand her very popular cosmetics line with the addition of a premium quality hand sanitizer based on her own proprietary formulation. With the high quality and care that Adrienne famously builds into all of her products, combined with her enormously loyal customer base, we believe this very well-timed \$3.5 million dollar hand sanitizer order, which we understand is an approximate four month supply for our customer, is just the beginning of a new and very exciting era for Dr Denese SkinScience", Morrison said.

"I have been fortunate during my 30+ years in the personal care space to have gained significant experience launching products and driving sales through a myriad of retail channels worldwide. Since the May 14 announcement that we were entering the multi-billion-dollar hand sanitizer market, I have taken the opportunity to discuss our new, premium grade hand sanitizer product with several large U.S. retail outlets. The reception we received was extremely positive. We are expecting substantial on-going growth in this exciting and innovative new product line", he added.

**Price:** 2.03

**Market Cap:** \$7.89 m

#### 1 Year Share Price Graph



December 2019 June 2020 December 20

#### Share Information

**Code:** PBIO

**Listing:** OTCQB

**52 week High Low**  
4.49 0.6006

**Sector:** Medical technology & services

**Website:** www.pressurebiosciences.com

#### Company Synopsis:

*Pressure BioSciences Inc. (OTCQB: PBIO): A leader in the sale of innovative, broadly enabling, pressure-based instruments and consumables for the worldwide life sciences industry.*

action@proactiveinvestors.com

Pressure BioSciences develops and sells pressure-based instruments, consumables, and platform technology solutions to the biotechnology, biotherapeutics, cosmeceuticals, nutraceuticals, and food and beverage industries.

Contact the author at [calum@proactiveinvestors.com](mailto:calum@proactiveinvestors.com)

Follow him on Twitter @Cal\_Proac

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Pressure BioSciences, Inc. named herein, including the promotion by the Company of Pressure BioSciences, Inc. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).